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Objective: Mitral valve repair with artificial chordae for degenerative mitral regurgi-
tation is widely adopted. We evaluated long-term results of mitral repair with
expanded polytetrafluoroethylene sutures (GORE-TEX CV-5; W. L. Gore & Associ-
ates, Inc, Flagstaff, Ariz).
Methods: Between November 1986 and November 2006, 608 consecutive patients
underwent mitral repair with artificial neochordae. Mean age was 55 6 11 years
(15–85 years); 433 (71.2%) were male. Valve disease was purely degenerative in
555 patients (91.3%). Prolapse of anterior, posterior, or both leaflets was present in
47 (7.7%), 308 (50.7%), and 253 (41.6%), respectively. Atrial fibrillation was asso-
ciated in 117 (19.2%). In 125 cases (20.5%), additional surgical procedures were per-
formed. Follow-up was complete at a median of 5.7 years (interquartile range 2.2–9.8
years, range 0–19.4 years).
Results: In-hospital mortality was less than 1% (6 deaths). Overall and cardiac late
mortalities were 6.6% and 3.9% (34 and 24 deaths). Kaplan–Meier survival at 15
years was 84% (95% confidence interval 75%–90%). Freedoms from endocarditis,
thromboembolic events, reoperation, and recurrent mitral regurgitation at 15 years
were 97% (95% confidence interval 93%–99%), 92% (87%–95%), 92% (88%–
95%), and 85% (78%–91%), respectively. Sinus rhythm was restored in 75% (33
patients) after surgical atrial fibrillation correction. Calcification of GORE-TEX
neochordae was never reported.
Conclusion: Mitral valve repair with GORE-TEX artificial chordae is effective, safe,
and associated with low operative mortality and low rates of valve-related complica-
tions at long-term follow-up. Artificial chordae showed excellent biologic adaptation,
retaining flexibility and tension with time.
M
itral valve (MV) repair has become the procedure of choice for the treat-
ment of mitral regurgitation (MR), with superior results relative to MV
replacement.1,2 MV repair is feasible in as many as 95% of cases of degen-
erative MV regurgitation,3 despite the presence of complex lesions. The Carpentier
quadrangular resection, with or without concomitant sliding plasty, is considered
the standard surgical technique to correct posterior leaflet prolapse.4 Various types
of reconstructive procedures, including triangular resection, chordal transfer, chordal
shortening, edge-to-edge technique, and papillary muscle repositioning, have been
used to repair anterior leaflet prolapse. MV repairs with these techniques are not al-
ways satisfactory, and some of these procedures are considered technically demand-
ing.4-6
Chordal replacement with expanded polytetrafluoroethylene (ePTFE) sutures
(GORE-TEX sutures; W.L. Gore & Associates, Inc, Flagstaff, Ariz) was introduced
experimentally by Frater and colleagues7 in the early 1980s. Current use in clinical
practice has permitted repair of complex mitral lesions with a now widely adopted
technique.3,8,9
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AF 5 atrial fibrillation
CI 5 confidence interval
ePTFE 5 expanded polytetrafluoroethylene
IQR 5 interquartile range
MR 5 mitral regurgitation
MV 5 mitral valve
SAM 5 systolic anterior motion
In this study, we report 20 years of experience of MV re-
pair with ePTFE suture in 608 consecutive patients. To our
knowledge, this is the largest reported series and the longest
follow-up study of this technique.
Patients and Methods
From 1986 to 2006, a total of 608 consecutive patients with severe
MR underwentMV repair with artificial neochordal implantation at our
institution. There were 433men (71.2%) and 175 women. Ages ranged
from 15 to 85 years (mean 55.56 11.5 years). Table 1 shows patients’
clinical profiles and the prolapsing leaflets. In cases of mild ascending
aorta dilation (5 patients) and absence of significant aortic valve disease
(3 patients), there was no concomitant surgical indication. The cause of
valve disease was purely degenerative in 555 patients (91.3%). Fifty-
three patients (8.7%) had degenerative MR complicated by infective
endocarditis. Atrial fibrillation (AF) was present in 117 patients
(19.3%). Coronary angiography was performed in patients older than
50 years and in those with suspected coronary artery disease.
Operative Procedures
The approach to the heart was exclusively by means of a midsternot-
omy until April 2006; since then, most of the operations have been
performed with a videoscopic port-access approach through a right
minithoracotomy. MV repair was performed with cardiopulmonary
bypass under moderate hypothermia. Myocardial protection was
achieved by both intermittent cold blood cardioplegia and topical
cooling for midsternotomy, whereas in minimally invasive surgery
cold crystalloid solution Custodiol (Koehler Chemie, Alsbach-
Haenlien, Germany) was infused. The MV was approached through
a standard left atriotomy with an incision made just behind the in-
teratrial groove. The entire MV apparatus was then carefully in-
spected, and prolapse of the leaflets was identified by examining
the level of the free margin of each portion of the leaflets. Resection
of the posterior leaflet according to the Carpentier technique4 was
performed in 351 patients (57.7%). Indications for GORE-TEX
chordoplasty, in combination with posterior leaflet resection, were
mainly as follows: (1) bileaflet prolapse (posterior resection plus
neochordae on anterior mitral leaflet); (2) need for a small posterior
mitral leaflet tissue resection to provide a better coaptation against
anterior mitral leaflet, with neochordal implantation mandatory in
this case to ensure a more stable connection between leaflet and pap-
illary muscles; and (3) Barlow disease, where reconstruction after
extensive posterior leaflet resection can leave an area without native
chordal support. Such technique was used less frequently in the last
few years. Actually, we prefer to resect only posterior mitral leaflet
tissue excess parallel to the margin. This means to resect an adequateThe Journal of Thorsegment of prolapsing tissue close to the free margin, to align P2
height with P1 height, when this scallop appears of normal size;
however, it creates a reduction that leaves about 1.5 cm height
from the annulus. Where ruptured or elongated chordae were at-
tached and resected, we replaced with ePTFE sutures.
Prolapse of the anterior leaflet was managed by chordal replace-
ment with ePTFE sutures only. Other techniques, such as triangular
resection, chordal transfer, or chordal shortening, have never been
used at our institution. We described the technique of chordal re-
placement with ePTFE suture in a previous publication.10 Briefly,
we use an ePTFE double-armed suture (GORE-TEX CV-5) that is
passed through the papillary muscle with a mattress technique and
is reinforced with autologous pericardial pledgets (or, rarely, with
GORE-TEX pledgets) on both sides of the muscle. Each end of
the suture is then fixed to the free margin of the prolapsed leaflet
and is reinforced with a small autologous pericardial pledget (or,
less frequently, a small GORE-TEX pledget). The length of the ar-
tificial chordae is adjusted tomaintain the corresponding free margin
of the leaflets at the desired level in the ventricular cavity. To deter-
mine the correct length of the artificial chordae so that an adequate
coaptation area is obtained and any significant prolapse is reduced,
the neochordae are tied at the end of all the other repair procedures
after the ventricular cavity is filled with saline solution.
In 48 selected cases (7.9%), after the leaflet repair was accom-
plished, if thin or fragile natural chordae tendineae were identified,
even if not elongated or ruptured, a couple of artificial chordae
were implanted as a protective function (‘‘sentinel’’ neochordae) to
TABLE 1. Clinical characteristics of patients with severe
mitral regurgitation
No. of patients 608
Age (y, mean 6 SD) 55.5 6 11.5
Male (No.) 433 (71.2%)
Electrocardiography (No.)
Sinus rhythm 491 (80.7%)
Atrial fibrillation 117 (19.3%)
Mitral valve pathology (No.)
Pure degenerative 555 (91.3%)
Degenerative plus endocarditis 53 (8.7%)
Prolapsing leaflet (No.)
Anterior 47 (7.7%)
Posterior 308 (50.7%)
Bileaflet 253 (41.6%)
New York Heart Association functional class (No.)
I 155 (26.7%)
II 270 (46.6%)
III 134 (23.1%)
IV 21 (3.6%)
Associated disease (No.)
Total cases 125 (20.5%)
Coronary artery disease 24 (3.9%)
Atrial septal defect or patent foramen ovale 43 (7.1%)
Aortic valve disease 14 (2.3%)
Tricuspid valve regurgitation 13 (2.1%)
Dilatation of ascending aorta 8 (1.3%)
Previous cardiac surgery (No.) 3 (0.5%)
Left ventricular ejection fraction ,40% 47 (7.7%)acic and Cardiovascular Surgery c Volume 135, Number 6 1281
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ceived only sentinel neochordae. These were placed as an extra sup-
port to ensure a better stability. According to Cox regression
analysis, no difference was found in terms of durability of the repair,
presence of significant MR, or mortality. Their precise role and,
eventually, possible protective factor should be the subject of
a deeper analysis of a larger series of patients. Most patients (99%)
underwent posterior annuloplasty. An autologous pericardial
band11 was used in 487 patients (80.1%), and rigid or flexible artifi-
cial rings were used in 116 patients (19.1%). The choice between
pericardium or prosthetic ring is determined by the surgeon’s prefer-
ence, anatomy, quality of pericardium, and age of the patient.
Implantation of a prosthetic ring is related to advanced age. We
adopted a quite simple method involving the Carpentier sizers and
the patient’s body surface area. We assume that a body surface
area smaller than 160 m2 would need Carpentier sizer number 32;
we therefore cut the pericardial band around the sizer. Between
1.60 and 1.80 m2, a 34 sizer was used, and above 1.80 m2, we
used the 36. In 5 cases we did not perform a pericardial or prosthetic
ring annuloplasty: 3 patients underwent simple suture annuloplasty,
and 2 had the annulus stabilized by calcification or fibrosis. Since the
year 2000, a surgical procedure for AF has been performed with
radiofrequency or microwave energy in 44 selected patients with
AF at hospital admission. Among these, 18 (41%) had permanent
AF; the remaining 26 (59%) had persistent AF. Another 12 radiofre-
quency ablations were performed for cases of paroxysmal AF but
were excluded from the count because patients had sinus rhythm
at admission.
In all cases, warfarin sodium for anticoagulation was adminis-
trated during the first 3 months after surgery and was discontinued
if sinus rhythm was established. Table 2 summarizes operative data.
Follow-up
Demographic, morphologic, echocardiographic, and surgical data
were obtained from hospital records. Patients were followed up at an-
nual intervalswith telephone interviews and echocardiographic stud-
ies. The median follow-up was 5.2 years (interquartile range [IQR]
1.8–9.0 years). Complete follow-up information was available for
602 survivors of the initial hospital stay (100%). The median fol-
low-up was 5.7 years (IQR 2.2–9.8 years, range 0–19.4 years).
Statistical Analysis
STATA software (version 9.2; StataCorp LP, College Station, Tex)
was used for all statistical analyses. Continuous values are expressed
as mean 6 SD or median and IQR. Comparisons between groups
were made with analysis of variance for continuous variables and
c2 test or Fisher exact test as appropriate for categoric variables.
Late survivals and freedoms from adverse events were estimated
with the nonparametric Kaplan–Meier method. Cox regression anal-
ysis with backward selection was used to identify the multivariable
and independent predictors of late outcomes. Variable retention in
the models was set at a P value of .05.
Results
Operative and Late Mortalities
There were 6 perioperative deaths (,1%), all related to low
cardiac output syndrome (Table 3). In 3 of these cases, the
MV was replaced for residual severe regurgitation (1 as a1282 The Journal of Thoracic and Cardiovascular Surgery c Juresult of medically intractable systolic anterior motion
[SAM]). Thirty-four deaths occurred during follow-up (24
cardiac-related deaths and 10 non–cardiac-related deaths).
The causes of cardiac-related death were heart failure
(n5 10), sudden cardiac death (n5 9), myocardial infarction
(n 5 3), and stroke (n 5 2). Cumulative survival at 15 years
was 84% (95% confidence interval [CI] 75%–90%; Figure 1).
TABLE 2. Operative data
Operations performed
Chordal replacement with e-PTFE 608 (100%)
Chordae replaced (No., mean and range) 6 (4–8)
Anterior chordal replacement 325 (53.5%)
Posterior chordal replacement 544 (89.5%)
Sentinel neochordae
Procedures 48 (7.9%)
No. placed (mean and range) 3 (2–6)
Resection of posterior leaflet 351 (57.7%)
Mitral annuloplasty 606 (99.7%)
None 2 (0.3%)
Suture annuloplasty 3 (0.5%)
Pericardial ring 487 (80.1%)
Artificial ring 116 (19.1%)
Additional procedures 214 (35.2%)
Atrial fibrillation surgical treatment 44 (7.2%)
Tricuspid valve repair 13 (2.1%)
Coronary artery bypass grafting 24 (3.9%)
Aortic valve replacement 6 (1%)
Aortic valve repair 5 (0.8%)
Repair of congenital atrioseptal defect 43 (7.1%)
Left atrial appendage closure 146 (24%)
Ascending aorta replacement 3 (0.5%)
Cardiopulmonary bypass time (min, mean 6 SD) 135.2 6 34.5
Crossclamp time (min, mean 6 SD) 109.1 6 31.3
All values are numbers (and percentages) of patients unless otherwise
specified. ePTFE, Expanded polytetrafluoroethylene.
TABLE 3. In-hospital morbidity and mortality
In-hospital mortality 6 (1.0%)
Perioperative morbidity 94 (15.5%)
Myocardial infarction 1 (1.1%)
Low cardiac output syndrome requiring IABP,
with or without VAD
5 (5.3%)
Heart failure 24 (25.6%)
Renal failure 9 (9.6%)
Respiratory insufficiency 13 (13.8%)
Stroke and transient ischemic attack 10 (10.6%)
Postoperative bleeding necessitating surgical
exploration
32 (34%)
Mitral regurgitation
.21 2 (0.3%)
21 10 (1.6%)
All values are numbers (and percentages) of patients. IABP, intra-aortic
balloon pump; VAD, ventricular assist device.ne 2008
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predictors of late death.
Perioperative Morbidity
Perioperative complications occurred in 94 patients (15.5%)
and are listed in Table 3. Three cases of significant SAM,
Figure 1. Long-term survival of patients with mitral valve repair
with GORE-TEX CV-5 expanded polytetrafluoroethylene suture.
TABLE 4. Cox regression analysis
Outcome
Hazard
ratio
95% Confidence
interval
P
value
Late mortality (n 5 34)
Age, 5-y increase 1.35 1.12–1.62 .002
Segmental resection of
posterior leaflet
0.45 0.22–0.92 .028
Associated CABG 2.85 1.66–15.24 .004
Perioperative stroke 8.90 1.81–43.77 .007
Perioperative myocardial
infarction
4.96 1.42–17.28 .012
Perioperative respiratory
insufficiency
5.39 1.52–19.13 .009
Cardiac-related mortality
(n 5 24)
Associated CABG 12.25 3.07–48.8 ,.001
Perioperative respiratory
insufficiency
9.17 2.76–30.50 ,.001
Reoperation on mitral valve
(n 5 25)
Age, 5-y increase 1.21 1.01–1.44 .042
Perioperative MR .2 12.97 3.58–44.82 ,.001
Moderate to severe MR (n 5 35)
Perioperative MR.2 12.57 4.14–38.14 ,.001
Segmental resection of
posterior leaflet
0.39 0.19–0.81 .012
Thromboembolic cerebral event
(n 5 21)
Perioperative stroke 9.67 1.21–77.15 .032
CABG, Coronary artery bypass grafting; MR, mitral regurgitation.The Journal of Thorarequiring a second pump run, were successfully treated
with the Alfieri edge-to-edge technique,5 whereas the other
3 cases were treated with volume adjustment and pharmaco-
logic therapy. Causes of SAM were undersized ring associ-
ated with quadrangular resection in 2 cases and ineffective
reduction of posterior mitral leaflet length in Barlow disease
in 4 cases.
Reoperation
Twenty-five reoperations (4.1%) were performed during the
follow-up period, 3 for MV infective endocarditis and the re-
mainder for progression of the degenerative disease. Overall
freedom from MV reoperation was 92% at 15 years (95% CI
88%–95%; Figure 2). No repair failures arising from sponta-
neous malfunction of GORE-TEX chordae were reported in
our series. Cox regression analysis showed that anterior leaf-
let prolapse was not an independent risk factor for reopera-
tion, recurrent MR, or mortality.
Infective Endocarditis
There were 7 cases (1.1%) of infective endocarditis; 3 pa-
tients underwent surgical treatment (2 replacements and 1
re-repair) and 4 were treated with antibiotic therapy. All
patients survived. In 1 case, a pair of artificial chordae
were involved in a large destruction of the corresponding
posterior leaflet and appeared ruptured. Freedom from en-
docarditis at 15 years was 97% (95% CI 93%–99%) for
all patients.
Thromboembolic Events and Anticoagulation-
Related Hemorrhage
Thromboembolic complications (transient ischemic attack
and stroke) were documented in 21 patients (3.5%). Four
patients (19%) had AF. Freedom from thromboembolism
at 15 years was 92% (95% CI 87%–95%) for all patients.
Since 1999, we have prophylactically closed the left atrial
appendage by direct suture in all patients, regardless of
Figure 2. Freedom from reoperation for all patients.cic and Cardiovascular Surgery c Volume 135, Number 6 1283
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bleeding episodes among patients who were receiving anti-
coagulation therapy. The freedom from major bleeding at
15 years was 96.5% (95% CI 87.6%–98.3%) for all
patients.
Recurrent MR
A grade of MR more than mild to moderate ($21) immedi-
ately after surgery was found in 12 patients (2%; Table 3).
Only 2 patients had greater than 21MR on leaving the oper-
ating room, a result of the lack of transesophageal echocardi-
ography; they were reoperated on a few days later. At the
beginning of our experience, we accepted even suboptimal
repair, considering that in some patients a second run of car-
diopulmonary bypass would be more life-threatening than
a 21MR. Among these patients, only 3 underwent reopera-
tion, and 1 died of sudden cardiac death. At follow-up, signif-
icant MR (more than moderate) was found in 35 patients
(5.8%), and 25 underwent reoperation. Overall freedom
from significant MR at 15 years was 85% (95% CI 78%–
91%; Figure 3). Cox regression analysis identified the pres-
ence of more than mild MR at discharge as an independent
risk factor for significant recurrent MR at follow-up (hazard
ratio 12.57, 95% CI 4.14–38.14; Table 4; Appendix E1).
Atrial Fibrillation
At follow-up, 76 patients (12.5%) had permanent AF. Since
2000, a surgical procedure for AF treatment has been per-
formed in 44 selected patients (7.2%). At follow-up, sinus
rhythm was restored in 33 patients (75%). New onset of
AF was seen in 40 patients (8.2% of 486) who were recorded
as having sinus rhythm before surgery.
Functional Status
Of 543 patients alive and free from reoperation at follow-up,
80.8% were in New York Heart Association functional class
I, 17.2% were in New York Heart Association functional
Figure 3. Freedom from recurrent moderate to severe mitral regur-
gitation for all patients.1284 The Journal of Thoracic and Cardiovascular Surgery c Junclass II, and 2.1% were in New York Heart Association func-
tional class III.
Discussion
MR caused by degenerative disease has been extensively
treated with valve repair, which has been shown to be supe-
rior to valve replacement in terms of operative mortality,
quality of life, and long-term survival. Symptom-free patients
also benefit from repair, with their survival after operation
found to be identical to that of general population.12
Since the introduction of standardized techniques for MV
reconstruction by Carpentier and others, numerous technical
improvements have been made in MV repair in the last 20
years, particularly in the treatment of anterior and bileaflet
MV prolapse.1 Efforts to find a substitute for elongated or
ruptured chordae date back to the 1960s. In 1962, January
and coworkers13 described a patient operated on ‘‘by placing
two 00 sutures through the base of papillary muscles and
through the margins of the unsupported portion of the mural
leaflet.’’ Frater and associates14 in 1965 published their expe-
rience with experimental and clinical use of autologous peri-
cardium as a chordal substitute.
In the 1980s, ePTFE sutures were evaluated indepen-
dently at three different institutions (Albert Einstein College
ofMedicine, NewYork, NY; Toronto Hospital, Toronto Uni-
versity, Toronto, Ontario, Canada; and Hospital Nacional
Marque´s de Valdecilla, Santander, Spain) in experimental
settings.7 The performance of this material was found to be
interesting. It permitted infiltration of tissue cells in its porous
microstructure, creating a firm adherence of the growing tis-
sue; at the same time, the tissue overgrowth was found to be
a self-limiting process.7,15 The ePTFE chordae were demon-
strated to be flexible, pliable, and resistant after months from
implantation, and they were introduced into clinical practice
in 1985.16,17
Chordal shortening showed significant limitations at fol-
low-up,18 and even if chordal transposition demonstrated su-
perior results, it was not always possible to find normal
healthy chordae at the opposite site of the prolapsing leaflet.
The risk of transferring diseased chordae during MV repair
can be avoided with implant of GORE-TEX artificial chor-
dae. Previous reports19-21 have shown good results at short
and intermediate follow-up. This report represents a 20-year
experience, and to our knowledge this is to date the largest ho-
mogeneous series of patients to undergo MV repair with
chordal replacement with ePTFE for whom the very long-
term follow-up beyond 15 years can be analyzed. Neochordal
implants could be associated with other classic procedures,
such as posterior annuloplasty or quadrangular resection of
the posterior leaflet with or without sliding. In our experience,
quadrangular posterior leaflet resection has constantly de-
creased during the most recent years without any increase
in rate of failure. Chordal replacement for prolapsed posterior
leaflet without quadrangular resection is currently oure 2008
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shows that quadrangular resection is a protective factor asso-
ciated with ePTFE chordae, but our change in operative strat-
egy has beenmotivated by the idea ofmaking the simplest and
most effective repair. Our current method saves crossclamp
time, preserves valve tissue, andmay obtain better coaptation.
Furthermore, it may avoid a small ring size annuloplasty, re-
sulting in a larger orifice.
GORE-TEX sutures appear to be an ideal material for syn-
thetic chordal replacement because of their biomechanical
properties, which ensure long-term durability and allow sur-
face endothelialization with normal fibrosa and intima.17
GORE-TEX sutures of 2-0 or 3-0 size seem to lose flexibility
with time, and tissue growth makes them stiffer in animal ex-
periments.22 Kobayashi and colleagues9 analyzed extracted
4-0 artificial chordae during reoperation and reported thick-
ening and stiffness of the explanted suture. For this reason,
they shifted to the 5-0 GORE-TEX suture implant. In 1990
in our institution, Zussa and associates22 demonstrated that
GORE-TEXCV 5-0 is a little thicker at explantation from hu-
man subjects but maintains length, flexibility, and resistance.
The extensive use of artificial chordae in cases of complex
lesions involving the anterior or both leaflets allows MV re-
pair in more than 95% of cases. We reached similar results
after 5 years, which is the time necessary for an adequate
learning curve. Amajor role was also played by the improved
accuracy of intraoperative transesophageal echocardiography
in the surgical planning and postoperative evaluation of MV
repair. Transesophageal echocardiography became available
in our institution in 1989, but routine intraoperative evalua-
tions have been obtained only since 1991. Previously, epicar-
dial echocardiography was performed in complex cases, but
the image quality was poor and sometimes unreliable.
Figure 4. Comparison of artificial and native chordae, seen at
reoperation after 12 years.The Journal of ThoraDetermination of the exact length of neochordae is a major
concern, and several methods have been described.10 The
technique we adopted is highly reproducible in both standard
midsternotomy and port-access minimally invasive settings.
Even in cases of acute endocarditis (53 patients), we em-
phasize that good results canbe achieved in a difficult scenario.
Neochordae were implanted as a substitute for infected natural
chordae.When patches of autologous or heterologous pericar-
dium were used to replace large areas of infected leaflets, arti-
ficial chordae were implanted to connect them to the papillary
muscles.
On the basis of our experience, we believe that there are
no clinical or anatomic contraindications for neochordal im-
plantation, although we have no experience of ePTFE artifi-
cial chordal implantation in children. In all our youngest
patients (17 patients, age range 15–30 years), the etiology
was pure degenerative myxomatous disease; in our opinion,
in this subgroup, it is almost mandatory to perform an annu-
loplasty with a pericardial band, instead of a prosthetic ring,
to make the repair most physiologically compatible. Our ex-
perience with pericardium is that such repairs are successful
and safe, and we have reported the absence of calcification
and the presence of complete endothelialization. Cox regres-
sion analysis demonstrates that a pericardial band is not pre-
dictive of repair failure. Further studies are needed to assess
the long-term results and echocardiographic features of the
pericardial band.
When prolapse occurs in fibroelastic deficiency, the leaflet
tissue is sometimes very thin. It is then mandatory to preserve
the posterior mitral leaflet, avoiding quadrangular resection
to prevent tissue laceration. Usually the free edge is thicker,
and neochordae can be safely anchored at this level.
Freedom from recurrence of moderate or severe MR was
high among our patients at 85% at 15 years. Our results are
comparable with those of David and colleagues,3 but our ex-
perience is 3 years longer. In Flameng and associates’ fol-
low-up work,23 a midterm follow-up study, freedom from
severe MR recurrence was low at 7 years (71%6 7.4%) rel-
ative to values in David and colleagues’ series3 (89% 6 2%
at 12 years) and our own. Moreover, in our series all patients
had GORE-TEX chordae implanted, whereas in both the
other studies, different techniques for MV repair were per-
formed. Even though in literature a very few cases of neo-
chordal rupture or calcification24-26 have been reported, in
this study the cause of reoperation and recurrent MR was
never related to spontaneous rupture or degeneration of im-
planted GORE-TEX sutures. Regarding the isolated epi-
sodes described in the literature, we hypothesize different
situations. The ePTFE sutures could be stretched or pinched
by forceps or clips at the time of implantation, and this con-
dition may have created a site of weakness. Otherwise, the
rupture could have been the consequence of inflammatory
process related to a subclinical endocarditis. In 25 reopera-
tions, only in 1 case of acute endocarditis did we detectedcic and Cardiovascular Surgery c Volume 135, Number 6 1285
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volved in a large erosion of the mural leaflet created by a se-
vere and destructive infective process. According to reports
of all reoperations performed in our center, artificial chordae
extracted were still as pliable, flexible, and resistant as the
native chordae (Figure 4). No calcification has been found
in explanted artificial chordae at various intervals after im-
plantation, nor has any been documented at echocardio-
graphic examination. Previously, other authors have found
this material to be free of calcification as late as 9 years after
implantation.27 No ischemia or rupture of the papillary mus-
cle at the site of implantation was recorded. According to
Cox regression analysis, the only independent risk factor
for reoperation is the presence of more than mild MR after
weaning from cardiopulmonary bypass. Interestingly, in
this series anterior leaflet prolapse was not observed as an in-
dependent predictor of reoperation, recurrent MR, or mortal-
ity. Moreover, assuming that bileaflet MV repair failures
were completely due to the anterior component, no signifi-
cant differences were found between this subgroup and those
involving the posterior leaflet alone. Further studies are nec-
essary to assess the precise mechanism of MV failure related
to the location of the prolapsing leaflet.
The predictability of the technique and the stability of the
results are demonstrated by the low long-term mortality, the
low rate of reoperation, and the high rate of freedom from
moderate to severe MR at 15 years. Thus artificial chordal
implantation, alone or in association with class techniques,
has good long-term results.
Limitation
This was a retrospective analysis and thus has some inherent
limitations and bias. Follow-up data were obtained from hos-
pitalmedical records, outside reports, and survey information.
We did not personally review any echocardiographic images
to assess MR grade but rather trusted that transthoracic echo-
cardiographywas performed according to the American Soci-
ety of Echocardiography guidelines. We recorded death
information as obtained through hospital records and public
demographic registry. Multivariable analyses were used to
control for disparities in preoperative risk factor profile. It
may be that these kinds of studies underestimate repair fail-
ures, but we believe that the recurrence of significant MR
and referral for surgical assessment were closely linked in
our patient population.
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sure for us to collaborate with R. W. M. Frater, who provided
the basis for the clinical application of the artificial chordae in
our center. We are grateful to Emanuele Di Angelantonio
from the University of Cambridge (UK) for the statistical1286 The Journal of Thoracic and Cardiovascular Surgery c Junanalysis of all data and to Roxane Zennaro for her technical
assistance in preparing the manuscript. Last, but not least,
we are grateful to Valeria Salandin and the anesthesiology
team, who supported and helped us constantly.
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Discussion
‘‘A 20-Year Experience of Mitral Valve Repair with Artificial Chor-
dae in 608 Patients.’’ Discussion by James I. Fann, M.D., Stanford,
CA.
Dr. James I. Fann (Stanford, CA) Loris, I wish to congratulate
you on a comprehensive presentation regarding the use of artificial
chordae replacement in the repair of degenerative mitral valve dis-
ease. Included in your series is isolated anterior or bileaflet prolapse
in nearly half the cases.What is impressive is the number of patients,
the excellent early and late results, and the length and completeness
of followup. It is believed that artificial chordae replacement in de-
generative disease and posterior leaflet prolapse in particular may
provide additional chordal support, maintain greater leaflet area, per-
mit for more complex repair, and has the potential of decreased rate
of failure.
My first question relates to the percentage of patients who had
isolated posterior leaflet prolapse which comprised nearly 50% or
51% of patients who underwent chordal replacement in your group’s
experience. Here is the question. Do you think that a segmental
leaflet resection and reconstruction with annuloplasty without
chordal replacement - do you think that would have been sufficient
in these patients or is chordal replacement absolutely necessary?
Dr. Salvador. Based on Cox regression analysis, we observed
that quadrangular resection of the posterior leaflet is a protective fac-
tor only if associated with artificial chordae implant. Actually, I am
not sure that the results would be the same without artificial chordae.
In the last years, we performed less frequently quadrangular re-
section and in this subgroup any redo was needed. In the first decade
of this series, when resection was widely adopted, it provided excel-
lent results, that made us pretty happy about performance at long-
term follow-up. I don’t know honestly how to explain why resectionThe Journal of Thorais a protective factor. I think that at the beginning of the experience,
without intraoperative TEE we couldn’t precisely analyze mitral
valve pathology. So we performed more quadrangular resections
of the posterior leaflet, the gold standard at that time, than we do
at present. I think that, in future, we will evaluate the long-term re-
sults of this strategy, as more and more patients without resection
will be included in a study.
Dr. Fann. From the surgical perspective, what technique do you
employ to optimize the length or to adjust the chordae. That is, how
do you size the length of the chordae? How do you size the ring for
the mitral valve repair?
Dr. Salvador. Despite many suggestions that you can find in lit-
erature, we always use one simple method. We fill-up the ventricle
with saline once the repair is completed. I mean after implanting the
ring, quadrangular resection, if needed, or commissural fusion and
whatever else you have to repair. At the very end, we fill the ventri-
cle and we decide: to push or pull the leaflet, up or down, until we
obtain a satisfactory coaptation. This is the only method we use. Af-
ter acquiring an adequate experience we do not even pay so much
attention to the length because it becomes something instinctual. I
don’t think is so fundamental to execute scientific measurements
about distance between papillary muscles and annulus or something
like this.
Dr. Fann. Do you oversize the annulus when you do the annu-
loplasty? I know you use the.
Dr. Salvador. Most of our patients had autologous pericardium
band implant and we adopt a very simple way to measure it, using
the Carpentier sizers based on the patient’s Body Surface Area.
We assume that a BSA under 1.60 Square Meters, need the Carpent-
ier’s number 32 and we cut the band around that sizer. Between 1.60
and 1.80 we use a 34 sizer and above 1.80 the 36 sizer.
Dr. Fann. And finally you report that a total of 12 patients with
more than 21MRwere found immediately after surgery. What was
the cause in these patients other than the those patients that you
reported that had SAM that also had 21 MR and how were these
patients treated postoperatively?
Dr. Salvador. Actually, the patients were discharged! Mostly,
this entity of post-operative MR was observed at the beginning of
the experience, however in a small percentage of patients: 12 out
of 608. First of all, I repeat, in the mid ’80, it was difficult to have
the echo in OR. At that time we had only normal transthoracic
echo so we accepted this grade of insufficiency if it was found after
leaving the OR. Right now it is a very rare event that a patient is dis-
charged with such grade of insufficiency and there must be a very
compelling reason. Today, it’s very rare also to be discharged
even with 11. At the beginning of the experience we accepted it,
considering that, in some patients, a second run of cardiopulmonary
bypass would have been more risky than a 21 mitral regurgitation.
Dr. Fann. Loris, thank you very much for an insightful presen-
tation. I appreciate it.
Dr. Salvador. Thank you.cic and Cardiovascular Surgery c Volume 135, Number 6 1287
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CDAPPENDIX E1: Variables included in Cox regression analysis of risk factors for death, reoperation, and presence of
significant mitral regurgitation
Demographic variables
Age
Sex
Mitral valve disease
Etiology
Prolapse or rupture of anterior leaflet
Prolapse or rupture of posterior leaflet
Prolapse or rupture of bileaflets
Annular calcification
Left ventricular function
Chronic heart failure
History of myocardial infarction
Cardiac comorbidity
Preoperative atrial fibrillation
Number of coronary arteries with more than 50% stenosis
Family history of coronary artery disease
Aortic valve disease
Ascending aorta dilation
Tricuspid valve disease
Repair
Date of repair
Use of annuloplasty
Type of annuloplasty
Leaflet resection
Sliding leaflet repair
Anterior leaflet chordal implant
Posterior leaflet chordal implant
Bileaflet chordal implant
Sentinel neochordal implant
Number of sentinel neochordae
Repair of residual defect in leaflet coaptation
Use of intraoperative echocardiography
Associated procedures
Appendage closure
Patent foramen ovale or interatrial septal defect closure
Coronary artery bypass grafting
Surgical ablation of atrial fibrillation
Tricuspid annuloplasty
Aortic valve surgery
Ascending aorta surgery
Crossclamp time
Cardiopulmonary bypass time
Perioperative mitral regurgitation
Perioperative morbidity1287.e1 The Journal of Thoracic and Cardiovascular Surgery c June 2008
